Search

Displaying results 8001 - 8010 of 10000 in total
  1. Drug

    Taberminogene vadenovec

    go.drugbank.com/drugs/DB05011
    Experimental

    The initial target market is haemodialysis graft access surgery, a procedure in which patients whose kidneys have failed have a plastic tube grafted between blood vessels generally in their forearm so … Taberminogene vadenovec (EG004) is a novel product consisting of a local delivery device and a gene-based medicine, being developed to prevent the blocking of veins and arteries that frequently occurs

  2. Drug

    Amonafide

    go.drugbank.com/drugs/DB05022
    Investigational

    Amonafide is a substance that is being studied in the treatment of cancer. It belongs to the families of drugs called topoisomerase inhibitors and intercalating agents.

    Salts: Amonafide L-malateCategories: Heterocyclic Compounds, 2-Ring, Compounds used in a research, industrial, or household setting
  3. Drug

    ATL1101

    go.drugbank.com/drugs/DB05023
    Experimental

    ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis. … ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis.

  4. Drug

    Lancovutide

    go.drugbank.com/drugs/DB05029
    Investigational

    Lancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis. … Lancovutide is a 19-amino-acid tetracyclic peptide produced by Streptoverticillium cinnamoneus and is closely related to cinnamycin (Ro09-0198). It belongs to the lantibiotics.

  5. Drug

    Votucalis

    go.drugbank.com/drugs/DB05032
    Investigational

    rEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.

  6. Drug

    INCB7839

    go.drugbank.com/drugs/DB05033
    Investigational

    INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. … It represents a potentially important new class of targeted breast cancer therapy. It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients.

  7. Drug

    Ularitide

    go.drugbank.com/drugs/DB05034
    Investigational

    Ularitide is currently in Phase 2 development as a potential treatment for patients with acute decompensated heart failure (ADHF). … Ularitide is a synthetic form of urodilatin, a naturally occurring human natriuretic peptide that is involved in regulating blood pressure and the excretion of water and sodium from the kidneys.

  8. Drug

    Eprotirome

    go.drugbank.com/drugs/DB05035
    Investigational

    Eprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia.

  9. Drug

    MVA3000

    go.drugbank.com/drugs/DB05040
    Experimental

    MVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or … skin conditions such as eczema.

  10. Drug

    SGS518

    go.drugbank.com/drugs/DB05042
    Experimental

    SGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).